Improve ultrapure water system performance and uptime with ozone

Companies often experience regulatory challenges during an inspection of aging facilities, requiring them to initiate projects to optimize product protection and updating to current standards for classified areas for biopharma manufacturing. For a long time, the company response has been to improve the existing classified areas or maybe even upgrading to a higher grade of classification. However, it may be more appropriate, and improve product protection, to instead implement the use of closed system processes and downgrade room classification during these facility renovation projects. If closed systems are fully utilized, then a CNC space can be used. As well as reducing the complexity of operations, this will reduce capital and operating costs.

We developed this platform to help you learn about our products, solutions and applications expertise on your own terms. Each booth contains valuable resources in the form of application notes, white papers, scientific posters, and other materials. We encourage you to review and download as much as you’d like. The virtual trade show is now the home of all our live and on-demand webinar programs, available for viewing any time. You can also view a list of upcoming live webinars by clicking the Webinars tab in the main navigation above. If this is your first time visiting, please complete the registration form on the right to gain access to the virtual trade show. Content is updated frequently, so come back often.

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder affecting some 40,000 individuals in Europe at any time, causing 10,000 deaths each year. As with other age-related neurodegenerative diseases, the drug development field is littered with inconclusive or negative trials. Modifying Immune Response and Outcomes in ALS (MIROCALS) is an international European Union H2020-funded trial of low-dose interleukin-2 in motor neuron disease (MND)/ALS. It aims to break this impasse in the development of disease-modifying agents through novel trial design, incident (early post-diagnosis) recruitment, integration of biomarkers/transcriptomics and cohort stratification. Join this webinar to hear about an overview of the study in addition to a discussion of the challenges both anticipated and unanticipated in recruiting participants recently diagnosed with a rare, rapidly disabling and ultimately life-limiting condition.

Heritable disorders can often be linked back to a specific gene or genetic variant which transmits the risk of disease across generations. In most cases, the penetrance, or risk of being affected by the disease, for a pathogenic variant carrier is less than 100%. For an increasing number of disorders, the penetrance is even lower (20-50%), which begins to confound our ability to understand the relationship between disease risk and a specific genetic variant. At this level, classical tools, including family and functional studies, for assessment of variant pathogenicity loose power. This webinar will address the utility of the different lines of evidence in the classification of variants in moderate penetrance disease and recommended modifications to multivariate analysis in this setting.